Gliomas Infiltrating the Corpus Callosum: A Systematic Review of the Literature.
butterfly glioma
corpus callosum
glioblastoma
neuro-oncology
survival
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
19 May 2022
19 May 2022
Historique:
received:
14
04
2022
revised:
01
05
2022
accepted:
18
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
Background: Gliomas infiltrating the corpus callosum (G-I-CC) majorly impact patient quality-of-life, but maximally safe tumor resection is challenging. We systematically reviewed the literature on G-I-CC. Methods: PubMed, EMBASE, Scopus, Web of Science, and Cochrane were searched following the PRISMA guidelines to include studies of patients with G-I-CC. Clinicopathological features, treatments, and outcomes were analyzed. Results: We included 52 studies comprising 683 patients. Most patients experienced headache (33%), cognitive decline (18.7%), and seizures (17.7%). Tumors mostly infiltrated the corpus callosum genu (44.2%) with bilateral extension (85.4%) into frontal (68.3%) or parietal (8.9%) lobes. Most G-I-CC were glioblastomas (84.5%) with IDH-wildtype (84.9%) and unmethylated MGMT promoter (53.5%). Resection (76.7%) was preferred over biopsy (23.3%), mostly gross-total (33.8%) and subtotal (32.5%). The tumor-infiltrated corpus callosum was resected in 57.8% of cases. Radiation was delivered in 65.8% of patients and temozolomide in 68.3%. Median follow-up was 12 months (range, 0.1−116). In total, 142 patients (31.8%) experienced post-surgical complications, including transient supplementary motor area syndrome (5.1%) and persistent motor deficits (4.3%) or abulia (2.5%). Post-treatment symptom improvement was reported in 42.9% of patients. No differences in rates of complications (p = 0.231) and symptom improvement (p = 0.375) were found in cases with resected versus preserved corpus callosum. Recurrences occurred in 40.9% of cases, with median progression-free survival of 9 months (0.1−72). Median overall survival was 10.7 months (range, 0.1−116), significantly longer in low-grade tumors (p = 0.013) and after resection (p < 0.001), especially gross-total (p = 0.041) in patients with high-grade tumors. Conclusions: G-I-CC show clinicopathological patterns comparable to other more frequent gliomas. Maximally safe resection significantly improves survival with low rates of persistent complications.
Identifiants
pubmed: 35626112
pii: cancers14102507
doi: 10.3390/cancers14102507
pmc: PMC9139932
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Références
Sci Rep. 2020 Oct 6;10(1):16630
pubmed: 33024247
Neuro Oncol. 2005 Jan;7(1):97-100
pubmed: 15701287
Nat Rev Cancer. 2020 Jan;20(1):57-70
pubmed: 31806884
Eur J Radiol. 2019 Mar;112:106-111
pubmed: 30777198
World Neurosurg. 2021 Oct;154:e734-e742
pubmed: 34358688
J Korean Neurosurg Soc. 2014 Sep;56(3):261-4
pubmed: 25368772
J Neurosurg. 2004 Mar;100(3):431-7
pubmed: 15035278
Acta Neurochir (Wien). 2022 Mar;164(3):689-702
pubmed: 34636967
Neurosurgery. 1982 Jul;11(1 Pt 1):68-72
pubmed: 7110572
J Neurooncol. 2022 Feb;156(3):635-644
pubmed: 35032284
Radiol Case Rep. 2021 Jul 15;16(9):2663-2667
pubmed: 34345327
BMJ Case Rep. 2021 Dec 30;14(12):
pubmed: 34969804
Nat Rev Clin Oncol. 2018 Feb;15(2):112-125
pubmed: 29158591
Acta Neurochir (Wien). 2021 Jul;163(7):1883-1894
pubmed: 33871698
J Neurol Neurosurg Psychiatry. 2005 Jun;76(6):845-51
pubmed: 15897509
J Neurooncol. 2019 Jan;141(1):167-182
pubmed: 30446902
Radiol Case Rep. 2020 Dec 03;16(2):319-326
pubmed: 33304444
J Neurooncol. 2012 Sep;109(3):555-63
pubmed: 22806339
Neurosurgery. 1992 Oct;31(4):741-5
pubmed: 1407461
J Neurooncol. 2015 Nov;125(2):393-400
pubmed: 26376654
J Clin Neurosci. 2009 Aug;16(8):1086-8
pubmed: 19409792
World Neurosurg. 2020 Dec;144:e156-e163
pubmed: 32795682
J Neurooncol. 2019 Sep;144(3):573-582
pubmed: 31410731
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Front Oncol. 2022 Feb 01;12:818446
pubmed: 35178348
Neuroimage. 2021 Feb 15;227:117642
pubmed: 33338619
Clin Neurol Neurosurg. 2011 Jun;113(5):407-10
pubmed: 21208740
J Neurooncol. 2017 Apr;132(2):341-349
pubmed: 28074322
J Neurooncol. 1998 May;38(1):83-9
pubmed: 9540061
J Clin Neurosci. 1999 Jan;6(1):68-70
pubmed: 18639131
Surg Neurol Int. 2020 Nov 06;11:372
pubmed: 33408906
J Neurooncol. 2021 Jun;153(2):273-281
pubmed: 33907967
BMJ Case Rep. 2016 Dec 15;2016:
pubmed: 27979842
Front Neurosci. 2021 Jul 30;15:701426
pubmed: 34393714
World Neurosurg. 2019 Jul;127:213-215
pubmed: 30974270
Am J Ophthalmol. 1970 Apr;69(4):594-8
pubmed: 5309572
Acta Neurochir (Wien). 2021 Apr;163(4):937-945
pubmed: 33095353
Singapore Med J. 2017 Mar;58(3):121-125
pubmed: 28361164
Neurosurg Focus. 2018 Jun;44(6):E4
pubmed: 29852771
World Neurosurg. 2018 Feb;110:e612-e620
pubmed: 29162526
J Neurooncol. 2005 Jul;73(3):239-40
pubmed: 15980974
World Neurosurg. 2020 Dec;144:162-169
pubmed: 32861903
Cancer Genet Cytogenet. 2007 Sep;177(2):125-30
pubmed: 17854667
Neurol Med Chir (Tokyo). 1990 Aug;30(8):604-9
pubmed: 1703639
J Clin Oncol. 2011 Oct 20;29(30):3999-4006
pubmed: 21931021
J Neurosurg. 2018 May;128(5):1438-1447
pubmed: 28686110
AMA Arch Neurol Psychiatry. 1958 Sep;80(3):298-303
pubmed: 13570745
J Neurooncol. 2014 Dec;120(3):625-34
pubmed: 25193022
N Engl J Med. 1949 Dec 22;241(25):1020-4, illust
pubmed: 15408539
Br J Neurosurg. 2004 Aug;18(4):391-5
pubmed: 15702843
J Neurooncol. 2015 Sep;124(2):207-14
pubmed: 26033546
Brain Tumor Pathol. 2011 Oct;28(4):305-9
pubmed: 21833577
Int Med Case Rep J. 2019 Jul 05;12:205-211
pubmed: 31308765
Acta Neurochir (Wien). 2020 Jul;162(7):1691-1699
pubmed: 32440925
J Clin Neurosci. 2019 Feb;60:153-155
pubmed: 30528355
Anticancer Res. 2022 Mar;42(3):1189-1198
pubmed: 35220208
Nat Cell Biol. 2020 Jan;22(1):97-107
pubmed: 31907411
JAMA. 2015 Apr 28;313(16):1657-65
pubmed: 25919529
World Neurosurg. 2019 Nov;131:174-176
pubmed: 31415896
J Neurosurg Sci. 2020 Jun;64(3):302-304
pubmed: 29671292
N Engl J Med. 2005 Aug 25;353(8):811-22
pubmed: 16120861
Acta Neurochir (Wien). 2009 Feb;151(2):137-40
pubmed: 19194655
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
J Neurosurg. 2021 Dec 14;:1-10
pubmed: 34905728
Cureus. 2020 Feb 7;12(2):e6914
pubmed: 32190469
Int J Radiat Oncol Biol Phys. 1997 Apr 1;38(1):27-30
pubmed: 9212000
Sci Rep. 2021 Jul 6;11(1):13934
pubmed: 34230597
Neurol Med Chir (Tokyo). 1998 May;38(5):283-6
pubmed: 9640964
J Neurooncol. 2021 Dec;155(3):215-224
pubmed: 34797525
NMC Case Rep J. 2019 Dec 18;7(1):39-41
pubmed: 31938681
J Neurosurg. 2017 Jun;126(6):1795-1811
pubmed: 27636183
J Cancer Res Ther. 2009 Jan-Mar;5(1):43-5
pubmed: 19293489
J Neurooncol. 2021 Dec;155(3):383-384
pubmed: 34800209
JAMA Oncol. 2016 Nov 01;2(11):1460-1469
pubmed: 27310651
Neuro Oncol. 2021 Oct 5;23(12 Suppl 2):iii1-iii105
pubmed: 34608945